ERBB2 and breast carcinoma: In contrast to our results, Mittal et al. demonstrated that higher ADORA2B gene expression levels correlate with shorter OS in a triple-negative breast cancer subset; however, this finding did not hold for luminal A, B, or HER2+ subsets of breast cancer [7].